A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
Launched by BRISTOL-MYERS SQUIBB · May 3, 2002
Trial Information
Current as of May 22, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion
- • relapsing-remitting MS
- • at least 1 exacerbation in preceding 2 years
- • at least 1 MRI lesion
- • stable for 2 months prior to dosing
- • Exclusion
- • progressive MS
- • currently treated with an immunomodulatory therapy
- • previously treated with an approved MS drug where treatment was discontinued for lack of efficacy
- • active bacterial or viral infections
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Louisville, Kentucky, United States
Worcester, Massachusetts, United States
Newark, New Jersey, United States
New York, New York, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
Dallas, Texas, United States
Burlington, Vermont, United States
Madison, Wisconsin, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials